Content about Teva Pharmaceuticals

May 14, 2013

Teva Health Systems has launched a generic injectable drug for small-cell lung cancer, the company said.

NORTH WALES, Pa. — Teva Health Systems has launched a generic injectable drug for small-cell lung cancer, the company said Tuesday.

Teva, a subsidiary of Teva Pharmaceuticals, itself a subsidiary of Israel-based Teva Pharmaceutical Industries, announced the launch of topotecan injection in the 1 mg-per-1 mL strength, in 4 mL, single-dose vials.

The drug is a generic version of GlaxoSmithKline's Hycamtin.

December 28, 2012

FDA approves NDA for Teva's topotecan injection

Teva Pharmaceuticals has received approval of their new drug application for topotecan hydrochloride injection, a treatment for small cell lung cancer, according to Food and Drug Administration records.

SILVER SPRINGS, Md. — Teva Pharmaceuticals has received approval of their new drug application for topotecan hydrochloride injection, a treatment for small cell lung cancer, according to Food and Drug Administration records.

December 28, 2012

Teva delays sales of Gilead generics pending court ruling

Teva Pharmaceuticals USA will delay the sales of generic versions of two Gilead Sciences HIV drugs until June 2013, the company stated.

NEW YORK — Teva Pharmaceuticals USA will delay the sales of generic versions of two Gilead Sciences HIV drugs until June 2013, the company stated. The decision comes pending a long-running patent suit in the U.S. District Court for the Southern District of New York.

Teva may launch generics for Truvada (i.e., emtricitabine/tenofovir disoproxil fumarate) and Viread (i.e., tenofovir disoproxil fumarate) on June 1 if there is no ruling holding that the patents-in-suit are invalid or unenforceable, according to an agreement filed between the drug makers Nov. 27.

November 12, 2012

Reports: P&G, Teva partner on European OTC company called PGT Healthcare, gain EU approval

Procter & Gamble and Teva Pharmaceutical on Monday gained European Union approval for a joint venture on the sale of nonprescription medicines to be called PGT Healthcare, according to published reports.

CINCINNATI — Procter & Gamble and Teva Pharmaceutical on Monday gained European Union approval for a joint venture on the sale of nonprescription medicines to be called PGT Healthcare, according to published reports.

According to the reports, the joint venture didn't raise competition concerns. P&G will have a 51% stake in the venture.

October 9, 2012

NewsBytes — Chain Pharmacy, 10/15/12

Drug maker Dr. Reddy’s Labs has launched a generic antibiotic drug, the company said. The India-based company announced the launch of amoxicillin tablets, capsules and oral suspension.

Dr. Reddy's launches antibiotics

October 5, 2012

FDA issues new guidelines for budeprion XL in the 300-mg strength

The Food and Drug Administration has reviewed new data that indicated that budeprion XL (bupropion hydrochloride extended-release tablets) in the 300-mg strength, manufactured by Impax Labs and Teva Pharmaceuticals USA, is not therapeutically equivalent to Wellbutrin XL in the 300-mg strength.

WASHINGTON — The Food and Drug Administration has reviewed new data that indicated that budeprion XL (bupropion hydrochloride extended-release tablets) in the 300-mg strength, manufactured by Impax Labs and Teva Pharmaceuticals USA, is not therapeutically equivalent to Wellbutrin XL in the 300-mg strength.

September 14, 2012

Impax, Teva settle with J&J, Alza over generic ADHD drug

Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

HAYWARD, Calif. — Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

Impax Labs and Teva Pharmaceuticals USA had settled a patent infringement suit with Janssen Pharmaceuticals and Alza over Concerta (methylphenidate hydrochloride) extended-release tablets in the 18-mg, 27-mg, 36-mg and 54-mg strengths.

July 18, 2012

Teva launches ADHD drug

Teva Pharmaceuticals has introduced a generic drug for treating attention deficit hyperactivity disorder, the company said.

NORTH WALES, Pa. — Teva Pharmaceuticals has introduced a generic drug for treating attention deficit hyperactivity disorder, the company said.

Teva announced the launch of methylphenidate hydrochloride extended-release capsules in the 20-mg, 30-mg and 40-mg strength. The drug, a generic version of Novartis' Ritalin, is available in 100-pill bottles.

May 17, 2012

FDA approves generic versions of Plavix

The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

April 3, 2012

Teva, Direct Relief USA donate $3 million in contraceptives

A drug maker and a charity organization are donating $3 million in contraceptives to uninsured women.

SANTA BARBARA, Calif. — A drug maker and a charity organization are donating $3 million in contraceptives to uninsured women.

Teva Pharmaceuticals and Direct Relief USA announced the donation of 5,000 units of the intrauterine contraceptive ParaGard to clinics and health centers serving low-income people, including the EXCELth Family Health Center in New Orleans.

March 29, 2012

Kline unveils 2011 drivers of U.S. OTC market

The U.S. over-the-counter drug market saw strong growth in 2011, thanks to switches of prescription drugs to OTC, gains in the allergy relief products category and holistic marketing, according to a new report from Kline.

PARSIPPANY, N.J. — The U.S. over-the-counter drug market saw strong growth in 2011, thanks to switches of prescription drugs to OTC, gains in the allergy relief products category and holistic marketing, according to a new report from Kline.

According to the international consulting and research firm's Nonprescription Drugs USA 2011 report, at the manufacturers' level, the U.S. OTC drug market posted a gain of 2.4%, reaching $21.4 billion in 2011.

February 3, 2012

Teva launches generic schizophrenia, bipolar disorder drug

Teva Pharmaceuticals has launched a generic version of a psychiatric drug, the company said Friday.

NORTH WALES, Pa. — Teva Pharmaceuticals has launched a generic version of a psychiatric drug, the company said Friday.

Teva announced the launch of olanzapine orally disintegrating tablets in the 5-mg, 10-mg, 15-mg and 20-mg strengths in blister packs of 30.

The drug is a generic version of Eli Lilly's Zyprexa Zydis, used to treat schizophrenia and bipolar disorder.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

December 7, 2011

HHS instructs FDA to decline proposal to move Plan B from BTC to OTC

The Department of Health and Human Services on Wednesday denied a request made by Teva Pharmaceuticals to relax merchandising restrictions for the emergency contraceptive Plan B.

WASHINGTON — The Department of Health and Human Services on Wednesday denied a request made by Teva Pharmaceuticals to relax merchandising restrictions for the emergency contraceptive Plan B. Presently, Plan B can be sold without a prescription to women older than 17 years old but only in a pharmacy and from behind the pharmacy counter. Women younger than 17 years require a prescription to acquire Plan B.

December 2, 2011

Six retailers charge Wyeth, Teva with unlawfully delaying generic Effexor XR

Six retailers on Wednesday filed suit naming Wyeth and Teva Pharmaceuticals as defendants and alleging that the defendants unlawfully delayed the entry of generic versions of Wyeth's antidepressant Effexor XR (venlafaxine).

TRENTON, N.J. — Six retailers on Wednesday filed suit naming Wyeth and Teva Pharmaceuticals as defendants and alleging that the defendants unlawfully delayed the entry of generic versions of Wyeth's antidepressant Effexor XR (venlafaxine). A summons was issued to Wyeth and Teva on Thursday.

The retailers include Ahold USA, H-E-B, Kroger, Safeway, Supervalu and Walgreens. The companies are suing for three-times damages plus attorneys fees.

Wyeth was acquired by Pfizer in October 2009.

July 29, 2011

Teva launches authorized generic of Seasonique

Teva Pharmaceuticals has launched an authorized generic version of a contraceptive made by Duramed Pharmaceuticals, Teva said.

JERUSALEM — Teva Pharmaceuticals has launched an authorized generic version of a contraceptive made by Duramed Pharmaceuticals, Teva said.

Teva announced the launch of Camrese, an authorized generic of Duramed’s Seasonique (levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets).

The launch of Teva’s authorized generic follows the launch of Watson Pharmaceuticals’ generic version of the drug, which it is marketing under the name Amethia.

April 13, 2011

FDA accepts regulatory application for Bio-T-Gel

The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

LINCOLNSHIRE, Ill. — The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

The two companies said the FDA had accepted their application for Bio-T-Gel and expected to complete its review by mid-November.

March 28, 2011

Teva launches chewable birth control pill

Teva Pharmaceuticals has launched a chewable birth control pill, the generic drug maker said Friday.

NORTH WALES, Pa. — Teva Pharmaceuticals has launched a chewable birth control pill, the generic drug maker said Friday.

Teva announced the launch of Zeosa (norethindrone and ethinyl estradiol) tablets.

The drug is chemically equivalent to Warner Chilcott’s Femcon Fe tablets and is available in the 0.4 mg/0.035 mg strength.

October 13, 2010

Teva markets generic Mirapex

Drug maker Teva Pharmaceuticals has launched a generic treatment for Parkinson’s disease, Teva said....

NORTH WALES, Pa. Drug maker Teva Pharmaceuticals has launched a generic treatment for Parkinson’s disease, Teva said.

The company announced the launch of pramipexole dihydrochloride tablets in the 0.75-mg strength.

The drug is a generic version of Boehringer Ingelheim’s Mirapex. Teva already offered the drug in the 0.125-mg, 0.25-mg, 0.5-mg, 0.75-mg, 1-mg and 1.5-mg strengths.

September 26, 2010

REPORTERS Notebook

Greenstone announced the launch of an authorized generic version of the Alzheimer’s disease drug Aricept...

September 1, 2010

Teva markets AcuDial generic

Teva Pharmaceuticals has launched a generic treatment for epileptic seizures....

NORTH WALES, Pa. Teva Pharmaceuticals has launched a generic treatment for epileptic seizures.

The world’s largest generic drug maker announced Wednesday the launch of diazepam rectal gel, a generic version of Valeant Pharmaceuticals’ Diastat AcuDial. The drug is administered via rectal syringe and is available in 2.5-mg, 10-mg and 20-mg strengths.